ACM
SRPT icon

Atika Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Atika Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,000
Closed -$4.26M – 122
2020
Q4 		$4.26M Buy
+25,000
New +$3.7M 0.33% 92
2020
Q1 		– Hold
0
– -$1.29M – 104
2019
Q4 		– Hold
0
– – – 67

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Atika Capital Management's SRPT Position: Q1 2021 in Review

Atika Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 59,100 shares — an estimated $10.1M sold.

Atika Capital Management first reported a position in SRPT in Q3 2017 and held it in 13 quarters. The position peaked at $14M in Q2 2019. 367 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

  • Atika Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Atika Capital Management sold 59,100 Sarepta Therapeutics shares in Q1 2021, an estimated $10.1M.
  • Atika Capital Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 13 quarters.
  • Atika Capital Management's Sarepta Therapeutics position peaked at $14M in Q2 2019.
  • 367 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Atika Capital Management's 13F filing for Q1 2021, filed 14 May 2021.